Literature DB >> 33277340

Frequency of Positive Aspergillus Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the Intensive Care Unit.

Erlangga Yusuf1, Alieke Vonk2, Johannes P C van den Akker3, Lonneke Bode2, Gregorius J Sips2, Bart J A Rijnders2, Jurriaan de Steenwinkel2, Nelianne J Verkaik2, Marius Vogel2, Menno van der Eerden4, Mireille van Westreenen2.   

Abstract

The aim of this study was to describe the frequency of positive Aspergillus tests in COVID-19 patients and investigate the association between COVID-19 and a positive Aspergillus test result. We compared the proportion of positive Aspergillus tests in COVID-19 patients admitted to the intensive care unit (ICU) for >24 h with two control groups: patients with community-acquired pneumonia with (i) a PCR-confirmed influenza infection (considered a positive control since the link between influenza and invasive aspergillosis has been established) and (ii) Streptococcus pneumoniae pneumonia (in whom positive Aspergillus tests are mostly considered as colonization). During the study period, 92 COVID-19 patients (mean [standard deviation] age, 62 [14] years; 76.1% males), 48 influenza patients (55 [14]; 56.2% males), and 65 pneumococcal pneumonia patients (58 [15], 63,1% males) were identified. Any positive Aspergillus test from any respiratory sample was found in 10.9% of the COVID-19 patients, 6.2% of the patients with pneumococcal pneumonia, and 22.9% of those infected with influenza. A positive culture or PCR or galactomannan test on bronchoalveolar lavage (BAL) fluid only was found in 5.4% of COVID-19 patients, which was lower than in patients with influenza (18.8%) and comparable to that in the pneumococcal pneumonia group (4.6%). Using logistic regression analysis, the odds ratio (OR) (95% confidence interval) for a positive Aspergillus test on BAL fluid for COVID-19 patients was 1.2 (0.3 to 5.1; P = 0.8) compared to the pneumococcal pneumonia group, while it was 0.2 (0.1 to 0.8; P = 0.02) compared to the influenza group. This difference remained significant when corrected for age and sex. In conclusion, in COVID-19 patients, the prevalence of a positive Aspergillus test was comparable to that in patients admitted for pneumococcal pneumonia but substantially lower than what we observed in patients with influenza.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  Aspergillus; COVID-19; galactomannan; invasive aspergillosis

Mesh:

Substances:

Year:  2021        PMID: 33277340     DOI: 10.1128/JCM.02278-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.

Authors:  Jackson S Musuuza; Lauren Watson; Vishala Parmasad; Nathan Putman-Buehler; Leslie Christensen; Nasia Safdar
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

2.  Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review.

Authors:  W H Chong; K P Neu
Journal:  J Hosp Infect       Date:  2021-04-21       Impact factor: 3.926

Review 3.  COVID-19 and Plethora of Fungal Infections.

Authors:  Reetu Kundu; Nidhi Singla
Journal:  Curr Fungal Infect Rep       Date:  2022-04-09

Review 4.  An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?

Authors:  R G Vitale; J Afeltra; S Seyedmousavi; S L Giudicessi; S M Romero
Journal:  Braz J Microbiol       Date:  2022-03-21       Impact factor: 2.214

5.  Usefulness of Sōna Aspergillus Galactomannan LFA with digital readout as diagnostic and as screening tool of COVID-19 associated pulmonary aspergillosis in critically ill patients. Data from a multicenter prospective study performed in Argentina.

Authors:  Gustavo Giusiano; Norma B Fernández; Roxana G Vitale; Christian Alvarez; María Eugenia Ochiuzzi; Gabriela Santiso; Matías Sebastián Cabeza; Fernanda Tracogna; Luciana Farías; Javier Afeltra; Luciana María Noblega; Carla Valeria Giuliano; Guillermo Garcia-Effron
Journal:  Med Mycol       Date:  2022-05-18       Impact factor: 3.747

Review 6.  A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA).

Authors:  Simon Feys; Maria Panagiota Almyroudi; Reinout Braspenning; Katrien Lagrou; Isabel Spriet; George Dimopoulos; Joost Wauters
Journal:  J Fungi (Basel)       Date:  2021-12-11

Review 7.  Epidemiology of Systemic Mycoses in the COVID-19 Pandemic.

Authors:  María Guadalupe Frías-De-León; Rodolfo Pinto-Almazán; Rigoberto Hernández-Castro; Eduardo García-Salazar; Patricia Meza-Meneses; Carmen Rodríguez-Cerdeira; Roberto Arenas; Esther Conde-Cuevas; Gustavo Acosta-Altamirano; Erick Martínez-Herrera
Journal:  J Fungi (Basel)       Date:  2021-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.